{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "Le cancer du col ut\u00e9rin est \u00e9vitable, au travers d\u2019une politique de pr\u00e9vention primaire et secondaire. Une vaccination contre le papillomavirus humain (HPV), et plus particuli\u00e8rement contre les HPV dits \u00e0 haut risque (HR-HPV) qui induisent le d\u00e9veloppement des \u00e9tats pr\u00e9canc\u00e9reux, permet ainsi d\u2019\u00e9viter une majeure partie de ceux-ci. Un d\u00e9pistage par cytologie \u00e0 la recherche de ces l\u00e9sions pr\u00e9canc\u00e9reuses (ou canc\u00e9reuses) peut \u00eatre supplant\u00e9 par la recherche de la pr\u00e9sence des HR-HPV. La pr\u00e9sence de HR-HPV sur le col doit faire suspecter une infection concomitante au niveau de l\u2019anus car les deux \u00e9pith\u00e9liums y sont tr\u00e8s sensibles. Cette attitude est dict\u00e9e par l\u2019augmentation des cancers de l\u2019anus dans la population, cancer lui aussi d\u00e9pendant du HPV, et donc aussi potentiellement \u00e9vitable au travers de la vaccination et du d\u00e9pistage."
      ]
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36259700",
  "DateCompleted": {
    "Year": "2022",
    "Month": "10",
    "Day": "21"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "10",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "fre"
    ],
    "ELocationID": [
      "10.53738/REVMED.2022.18.800.1950"
    ],
    "Journal": {
      "ISSN": "1660-9379",
      "JournalIssue": {
        "Volume": "18",
        "Issue": "800",
        "PubDate": {
          "Year": "2022",
          "Month": "Oct",
          "Day": "19"
        }
      },
      "Title": "Revue medicale suisse",
      "ISOAbbreviation": "Rev Med Suisse"
    },
    "ArticleTitle": "[Human Papillomavirus: screening of cervical and anal cancers].",
    "Pagination": {
      "StartPage": "1950",
      "EndPage": "1955",
      "MedlinePgn": "1950-1955"
    },
    "Abstract": {
      "AbstractText": [
        "Cervical cancer is preventable through primary and secondary prevention. Vaccination against the human papillomavirus (HPV), the virus necessary for the development of precancerous lesions, can prevent most of them. Screening by cytology for these precancerous (or cancerous) lesions can be replaced by screening for certain types of HPV, high risk (HR-HPV), causing cervical cancer. The presence of HR-HPV on the cervix should raise suspicion of concomitant infection in the anus, as both epithelia are highly susceptible. This attitude is dictated by the increase incidence in anal cancer in the population, which is also HPV-dependent and therefore also potentially preventable through vaccination and screening."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de gyn\u00e9cologie-obst\u00e9trique, D\u00e9partement femme-m\u00e8re-enfant, Centre hospitalier universitaire vaudois, 1011 Lausanne."
          }
        ],
        "LastName": "Pache",
        "ForeName": "Basile",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de gyn\u00e9cologie-obst\u00e9trique, D\u00e9partement femme-m\u00e8re-enfant, Centre hospitalier universitaire vaudois, 1011 Lausanne."
          }
        ],
        "LastName": "Jacot-Guillarmod",
        "ForeName": "Martine",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de chirurgie visc\u00e9rale, Centre hospitalier universitaire vaudois, 1011 Lausanne."
          }
        ],
        "LastName": "H\u00fcbner",
        "ForeName": "Martin",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de gyn\u00e9cologie-obst\u00e9trique, D\u00e9partement femme-m\u00e8re-enfant, Centre hospitalier universitaire vaudois, 1011 Lausanne."
          }
        ],
        "LastName": "Mathevet",
        "ForeName": "Patrice",
        "Initials": "P"
      }
    ],
    "PublicationTypeList": [
      "English Abstract",
      "Journal Article"
    ],
    "VernacularTitle": "Papillomavirus humain\u2009: d\u00e9pistage des cancers du col et de l\u2019anus."
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Rev Med Suisse",
    "NlmUniqueID": "101219148",
    "ISSNLinking": "1660-9379"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Papillomavirus Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Papillomaviridae"
    },
    {
      "QualifierName": [
        "pathology"
      ],
      "DescriptorName": "Cervix Uteri"
    },
    {
      "QualifierName": [
        "diagnosis",
        "epidemiology",
        "prevention & control"
      ],
      "DescriptorName": "Uterine Cervical Neoplasms"
    },
    {
      "QualifierName": [
        "complications",
        "diagnosis",
        "epidemiology"
      ],
      "DescriptorName": "Papillomavirus Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Alphapapillomavirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Early Detection of Cancer"
    },
    {
      "QualifierName": [
        "diagnosis",
        "epidemiology",
        "prevention & control"
      ],
      "DescriptorName": "Anus Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Papillomavirus Vaccines"
    }
  ],
  "CoiStatement": "La Dre Martine Jacot-Guillarmod est membre du comit\u00e9 consultatif sur la vaccination HPV chez MSD. L\u2019entier des honoraires est revers\u00e9 au CHUV. Les autres auteurs n\u2019ont d\u00e9clar\u00e9 aucun conflit d\u2019int\u00e9r\u00eats en relation avec cet article."
}